TORONTO, March 30, 2015 /CNW/ - Richard Muruve, CEO and Director, Arch Biopartners Inc. (ACH) joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange. Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for medical needs. The Company's portfolio includes MetaMxTM which targets brain tumor initiating cells. Arch Biopartners is developing new treatments for Pseudomonas aeruginosa respiratory infections, inflammation based diseases, sepsis and cancer metastasis. Arch Biopartners Inc. commenced trading on TSX Venture Exchange on February 23, 2015.
SOURCE Toronto Stock Exchange
Image with caption: "Richard Muruve, CEO and Director, Arch Biopartners Inc. (ACH) joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange. Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for medical needs. The Company’s portfolio includes MetaMx(TM) which targets brain tumor initiating cells. Arch Biopartners is developing new treatments for Pseudomonas aeruginosa respiratory infections, inflammation based diseases, sepsis and cancer metastasis. Arch Biopartners Inc. commenced trading on TSX Venture Exchange on February 23, 2015. (CNW Group/Toronto Stock Exchange)". Image available at: http://photos.newswire.ca/images/download/20150330_C7807_PHOTO_EN_13699.jpg
please visit www.archbiopartners.com.Copyright CNW Group 2015